Lantheus Medical Imaging has entered into national contract with Novation for Ablavar (gadofosveset trisodium) and Definity Vial For (Perflutren Lipid Microsphere) Injectable Suspension, to increase diagnostic imaging agents access for health care providers.
The diagnostic imaging agents like Ablavar, a blood pool contrast agent, and Definity, a cardiac ultrasound contrast agent, can help physicians in the diagnosis and treatment of disease with improved image quality.
Ablavar makes it possible for physicians to detect vascular disease using MRA, which is less invasive than conventional X-ray angiography, the current standard of care, and without exposing patients to ionizing radiation.
Definity is used to improve image quality in patients with suboptimal echocardiograms.
Lantheus Medical Imaging Sales and Marketing vice president Robert Spurr said Ablavar is a magnetic resonance angiography (MRA)blood pool imaging agent indicated for evaluation of aortoiliac disease (AIOD) in adults with known or suspected peripheral vascular disease, while Definity is used in patients with suboptimal echocardiograms to opacify the left ventrical chamber and to improve the delineation of the left ventricular endocardial border.